KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Dicembre 2024 - 12:30PM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that the compensation committee of KalVista’s board of directors
granted five newly-hired employees inducement options to purchase
an aggregate of 36,000 shares of KalVista common stock on December
2, 2024 as inducements material to each employee entering into
employment with KalVista. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $10.27 per share, which
was equal to the closing price of KalVista common stock on the
grant date. One-fourth of the options vest on the one-year
anniversary of the vesting commencement date and the remainder vest
in equal monthly installments over the next three years, in each
case subject to the new employee’s continued service with the
company. Each stock option has a 10-year term and is subject to the
terms and conditions of KalVista’s Inducement Equity Incentive Plan
and a stock option agreement covering the grant.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical
company whose mission is to develop and deliver life-changing oral
medicines for people affected by rare diseases with significant
unmet needs. Sebetralstat, our novel, investigational candidate for
the oral, on-demand treatment of hereditary angioedema, is under
regulatory review by the FDA with a PDUFA goal date of June 17,
2025. In addition, we have completed Marketing Authorization
Application (MAA) submissions for sebetralstat to the European
Medicines Agency and the United Kingdom, Switzerland, Australia,
and Singapore.
For more information about KalVista, please visit
www.kalvista.com or follow on social media at @KalVista and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241204815613/en/
KalVista Pharmaceuticals, Inc. Media: Jenn Snyder
Vice President, Corporate Affairs (857) 356-0479
jennifer.snyder@kalvista.com Investors: Ryan Baker Head,
Investor Relations (617) 771-5001 ryan.baker@kalvista.com
Grafico Azioni KalVista Pharmaceuticals (NASDAQ:KALV)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni KalVista Pharmaceuticals (NASDAQ:KALV)
Storico
Da Dic 2023 a Dic 2024
